{
    "N/R/U": null,
    "Applicant": "Swedish Orphan Biovitrum AB (publ)",
    "BLA Number": "103770",
    "Proprietary Name": "Synagis",
    "Proper Name": "palivizumab",
    "BLA Type": "351(a)",
    "Strength": "100MG/1ML",
    "Dosage Form": "Injection ",
    "Route of Administration": "Intramuscular",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "23-Jul-04",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "5059",
    "Submission Type": "Supplement",
    "License Number": "1859",
    "Product Number": "4",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}